Category: Diabetes

Introduction and Objective: Proximal Intestinal Mucosal Ablation (PIMA) is a new endoscopic procedure to treat type 2 diabetes (T2D). PIMA replicates the metabolic benefits of gastric bypass surgery by ablating up to 75 cm of the post-ampullary intestinal mucosa with radiofrequency vapor ablation (RFVA). Similar technologies, limited to 15cm of duodenal mucosa, have attempted to […]

Introduction and Objective: Type 2 diabetes (T2D) is frequently associated with hepatic complications like fatty liver and fibrosis named Metabolic dysfunction associated steatotic liver disease (MASLD).This study evaluates the demographic profile, Body Mass Index (BMI) and liver health parameters— Fibrosis-4 (FIB-4) score, Controlled Attenuation Parameter (CAP) score and Liver Stiffness Measurement (LSM)Methods: A total of […]

Introduction and Objective: MET-233 is an ultra-long acting (ULA) amylin analog being evaluated in clinical trials for the treatment of obesity. We sought preclinical proof of concept that MET-233, designed to be combined with GLP-1R agonist MET-097, is an effective candidate for obesity treatment.Methods: MET-233 emerged from an amylin analog development program focused on potency, […]

Introduction and Objective: This study evaluated the prevalence of food insecurity (FI) among adults with diabetes initiating continuous glucose monitoring (CGM) therapy compared to national averages and examined associations with gender, age, and glycemic outcomes.Methods: Fifty adults initiating CGM therapy were screened for FI using the USDA Six-Item Short Form. Individuals with an FI score […]

Introduction and Objective: A short-term study in obese T2D patients showed that the combination of dorzagliatin, a glucokinase activator (GKA) and sitagliptin improved glucose controls with increased GLP-1 secretion. This study aims to assess the impact of long-term administration of dorzagliatin and the combination of dorzagliatin/sitagliptin on glucose homeostasis in high-fat diet-induced obesity/diabetes (DIO) mice.Methods: […]

Introduction and Objective: CK-0045 is a novel long-acting IL-22 receptor agonist with great potential for treatment of patients with metabolic diseases based on preclinical data. Here we present the results of a randomized, double-blind, placebo-controlled, Phase 1 study investigating safety, tolerability, and pharmacokinetics of CK-0045 in healthy participants with and without obesity.Methods: A total of […]

Introduction and Objective: Few studies have explored the experiences of people newly diagnosed with type 2 diabetes (T2D). This study aimed to understand these experiences through in-depth interviews to identify unmet psychosocial needs.Methods: Thirty adults with T2D diagnosed within the past six to nine months were interviewed using a semi-structured guide to capture their experiences […]

Introduction and Objective: Teplizumab is the first therapeutic to demonstrate the ability to delay progression from stage 2 to stage 3 type 1 diabetes (T1D). In this extension of the TrialNet stage 2 teplizumab study (TN-10), we followed participants who received a course of teplizumab after developing stage 3 T1D.Methods: TN-10 Extension was a multicenter, […]

Introduction and Objective: The causes and management of diabetes are widely misunderstood. The prevailing narrative misrepresents diabetes as a self-inflicted condition, attributed to laziness, gluttony, and irresponsibility. While many health care professionals are supportive, evidence suggests biases exist in diabetes care. The purpose of this study was to examine if these biases develop early in […]

Introduction and Objective: Obesity and type 2 diabetes are associated with mitochondrial dysfunction and reduced plasticity of white adipose tissue (WAT), characterized by impaired adaptive responses to metabolic demands. miR-22 plays a key role in lipid metabolism dysregulation, and its inhibition has been shown to restore metabolic homeostasis in preclinical models. RES-010, a first-in-class antisense […]